Abstract Details

Title Cerebral Blood Flow Velocity and Autoregulation in Adolescents at Three Different Altitudes

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P01 - (-)

Poster/Presentation
Number 244

Objective

Background BACKGROUND: High altitude Peruvians show high prevalence of Chronic Mountain Sickness. It has been demonstrated that high altitude Peruvians have an impairment of cerebrovascular reactivity. This impairment could also explain this high prevalence of Chronic Mountain Sickness. The cerebral autoregulation is based on the capacity of response of the cerebral vessels to modify its diameter. The studies have been done over 3000 meters over the sea level, and there are no data about the cerebral autoregulation to middle altitudes.

Design/Methods DESIGN/METHODS: We study the cerebral blood flow velocity at the right medial cerebral artery and the cerebrovascular reactivity with hyperventilation, breath holding and total rang of vasodilatation using transcranial doppler. The study was carried on 90 adolescents of the cities of Camana (0 meters over sea level), Arequipa (2350 meters) y Juliaca (3820 meters).

Results RESULTS: There was no significant differences between the blood flow velocities in the adolescents at the three altitudes. We found a statistically reduction in the cerebrovascular reactivity after hyperventilation, breath holding and total rang of vasodilatation between the adolescents of the cities of Arequipa and Juliaca compared with the adolescents of the city of Camana.

Conclusions CONCLUSIONS: There is a significant reduction in the cerebrovascular reactivity in intermediate and high altitudes, this reduction could explain the high prevalence of Chronic Mountain Sickness in intermediate altitude residents. This reduction in cerebrovascular reactivity could be a disadvantage response for high altitude living.

Authors/Disclosures
Cesar Caparo, MD PRESENTER	Dr. Caparo has nothing to disclose.
Sally Dunaway, DPT (Stanford University)	Dr. Dunaway has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Dunaway has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche/Genentech. Dr. Dunaway has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Scholar Rock. Dr. Dunaway has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Cure SMA. The institution of Dr. Dunaway has received research support from Cure SMA. The institution of Dr. Dunaway has received research support from Scholar Rock. The institution of Dr. Dunaway has received research support from Ionis Pharmaceuticals.

��ɫ��

��ɫ��